EGFR and cancer: A prospective phase II clinical trial of cetuximab in RAS wild-type mCRC patients combined the sequential profiling of ctDNA and matched tissue biopsies with imaging and mathematical modeling of cancer evolution, showing that liquid biopsies were able to detect spatial and temporal heterogeneity of resistance to anti-EGFR monoclonal antibodies [38].